Rheumatoid Arthritis. Rheumatoid arthritis, unspecified
Conditions
Interventions
Intervention 1: Intervention group: brewed tea of poulk (daily consumption of 2.4 gram dried powder of poulk with 2.4 gram dried powder of black tea), for 8 weeks (2 times a day, after lunch and dinne
Treatment - Other
Placebo
Intervention group: brewed tea of poulk (daily consumption of 2.4 gram dried powder of poulk with 2.4 gram dried powder of black tea), for 8 weeks (2 times a day, after lunch and dinner, each time dri
Control group: brewed black tea (daily consumption of 2.4 gram dried powder of black tea, for 8 weeks (2 times a day, after lunch and dinner, each time the dried powder of black tea in 240 ml boiled w
Sponsors
Connective Tissue Diseases Research Center
Eligibility
Sex/Gender
Female
Age
30 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Subjects diagnosed with rheumatoid arthritis based on American College of Rheumatology and European League Against Rheumatism (ACR-EULAR) 2010 criteria for RA; Desire to attend in the study and signing the informed consent form; Desire to fill in the questionnaires and participate in sampling; Age range of 30 to 65 years; Being diagnosed with active rheumatoid arthritis (disease activity score-28 more than 3.2); Not receiving antioxidant or anti-inflammatory supplements since one month prior to the study Exclusion criteria: Pregnancy; Lactation; Presence or history of other kinds of diseases and cancers; Other acute or chronic inflammatory diseases (such as colitis, psoriasis); AIDS; Sepsis; Type 2 diabetes mellitus; Thyroid disorders; Having side effects with poulk consumption besides drug side effects; Severe obesity (body mass index more than 40); Taking antioxidant supplements during the study; Smoking or being a passive smoker; Changing diet, physical activity and lifestyle during the study period; Unwillingness to continue the study
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical Outcomes (disease activity score in 28 joints). Timepoint: Before and after the 8-week intervention. Method of measurement: Using validated questionnaire.;Serum levels of inflammatory factors (intelukin-1, tumor necrosis factor-alpha, high sensitive-c reactive protein). Timepoint: Before and after the 8-week intervention. Method of measurement: Using commercially available kits and ELISA method.;Serum levels of matrix metalloproteinases: matrix metalloproteinase-1 and matrix metalloproteinase-3. Timepoint: Before and after the 8-week intervention. Method of measurement: Using commercially available kits and ELISA method. | — |
Secondary
| Measure | Time frame |
|---|---|
| Dietary intake of energy and nutrients. Timepoint: Before and after the 8-week intervention. Method of measurement: Using 3-day dietary record.;Anthropometric parameters (height, weight, body mass index, waist and hip circumferences). Timepoint: Before and after the 8-week intervention. Method of measurement: Body weight is measured using a calibrated scale (Seca, Germany) to the nearest 0.5 kilogram. Standing height without shoes and circumferences of waist and hip are measured using a non-stretchable tape (Seca) to the nearest 0.5 centimeters. Body mass index is calculated through dividing weight (kilogram) by the height squared (meters). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Saeed Pirouzpanah
Faculty of Nutrition, Tabriz University of Medical Sciences
Outcome results
None listed